EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Current Role of Antiangiogenics in Colorectal Cancer

Debora Basile iD, Paola Di Nardo iD, Maria Grazia Daffinà, Carla Cortese, Jacopo Giuliani iD, Giuseppe Aprile

International Journal of Molecular Sciences · 29.11.2025 · 26 (23) · 11605

DOI: 10.3390/ijms262311605 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.11.2025. Verfasst von Debora Basile und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology, San Giovanni Di Dio Hospital-Crotone, 88900 Crotone, Italy. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Angiogenesis Inhibitors, Neovascularization, Pathologic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal carcinoma (CRC) represents the third most common cancer worldwide. Approximately 20% of patients present with metastatic disease at diagnosis, and 30–50% experience disease recurrence over time. For metastatic CRC (mCRC), the standard treatment consists of chemotherapy combined with a targeted agent based on molecular profile, such as RAS, BRAF, and MSI status. Anti-angiogenic drugs, which inhibit the formation of new blood vessels, have an established role in the management of mCRC. Mounting evidence highlights the critical interplay among angiogenesis, hypoxia, and the immune response in tumor progression. These insights have paved the way for testing novel combinations and molecules to control cancer progression. In particular, combining anti-angiogenic agents with immune checkpoint inhibitors has shown promise in improving outcomes for mCRC patients. Among emerging therapies, the novel anti-angiogenic agent fruquintinib has recently demonstrated clinical efficacy in the treatment of mCRC. Based on the data discussed in the present narrative review, the therapeutic landscape of mCRC appears poised for significant evolution in the near future. While numerous challenges and unanswered questions remain, the emergence of innovative therapeutic combinations and agents provides a promising opportunity for improving patient outcomes in mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAngiogenesis InhibitorsNeovascularization, PathologicHumansAnimals

Stichwörter der Autor:innen

CRCanti-VEGFantiangiogenicscolorectal cancer

Substanzen

Angiogenesis Inhibitors

Autor:innen und Institutionen

  • Unit of Medical Oncology, San Giovanni Di Dio Hospital-Crotone, 88900 Crotone, Italy.
  • Department of Medical Oncology, Centro di Riferimento Oncologico (CRO), IRCCS, 33081 Aviano, Italy.
  • Unit of Medical Oncology, Giovanni Paolo II Hospital-Lamezia, ASP Catanzaro, 88046 Lamezia Terme, Italy.
  • Department of Oncology, Mater Salutis Hospital, Az. ULSS 9 Scaligera, 37045 Legnago, Italy.
  • Department of Oncology, Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy.

ORCID-Profile: Debora Basile, Paola Di Nardo, Jacopo Giuliani

Zitieren

APA

Basile, D., Di Nardo, P., Daffinà, M. G., Cortese, C., Giuliani, J., & Aprile, G. (2025). The Current Role of Antiangiogenics in Colorectal Cancer. International Journal of Molecular Sciences, 26(23), 11605. https://doi.org/10.3390/ijms262311605

Vancouver

Basile D, Di Nardo P, Daffinà MG, Cortese C, Giuliani J, Aprile G. The Current Role of Antiangiogenics in Colorectal Cancer. International Journal of Molecular Sciences. 2025;26(23):11605. doi:10.3390/ijms262311605

BibTeX
@article{Basile2025,
  author = {Basile, Debora and Di Nardo, Paola and Daffinà, Maria Grazia and Cortese, Carla and Giuliani, Jacopo and Aprile, Giuseppe},
  title = {The Current Role of Antiangiogenics in Colorectal Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {23},
  pages = {11605},
  doi = {10.3390/ijms262311605}
}
Kostenlos starten →